VIDO-InterVac

2 0 1 1 - 2 0 1 2 A N N U A L R E P O R T V I D O -I n t e r V a c
VIDO-InterVac
Vaccine and Infectious Disease Organization International Vaccine Centre
VIDO-InterVac
I
2011-2012
I
Annual Report
I
page 2
Table of Contents
VIDO-InterVac Mission and Vision ........3
Board of Directors and
Senior Management Team ...................3
Developing creative,
proactive strategies for
continued future success
Message from the Board Chair
of VIDO-InterVac, Dr. Robert Clarke ............4
World class resources
and expertise poised to meet
future challenges
Message from the Director
and CEO, Dr. Andrew Potter ......................6
Identify and prioritize
infectious disease targets
for vaccine development
Dr. Volker Gerdts, Associate Director
(Research).................................................8
Board/Senior Management Team: Back row L to R: Robert Clarke, Paul Hodgson, Don Wilson,
David Gordon, Cam Ewart, Volker Gerdts, Lorne Vanin. Front Row L to R: Andrew Potter, Terry Oleksyn,
Joyce Sander, John LaClare, Luis Barreto, Bill Ballantyne. Missing: Rainer Engelhardt, Chris Dekker,
Larry Milligan, Alastair Cribb, Karen Chad, Douglas Freeman
Nuturing innovation in
a diverse talent pool
Ms. Joyce Sander, Associate Director
(Human Resources) .................................13
Cutting edge containment
certification in sight
Mr. Cam Ewart, Associate Director
(Operations & Maintenance) ....................14
Expanded opportunities
to impact the world
Dr. Paul D. Hodgson, Associate Director
(Business Development) ..........................16
Managing resources
for future challenges
Mr. Lorne Vanin, Associate Director
(Finance) .................................................17
Our Mission
Our Vision
To be a pre-eminent research
Protecting the world from
institute investigating the
infectious diseases
pathogenesis of infectious
diseases and the development
of effective therapeutic and
prophylactic methods to control
infectious diseases of humans
and animals
Statement of Financial Position..........18
Statement of Operations .....................18
Review Statement ...............................19
VIDO-InterVac Contributors ................19
VIDO-InterVac
I
2011-2012
I
Annual Report
I
page 3
T
Message from
the Board Chair
his past year was an exceptional
facilitate the transfer of knowledge to solve
time in the life of VIDO-InterVac. The
disease problems in all species.
opening of our new facility has
As we move forward, the Board is confident
created unique opportunities for our scientists
that the management and scientific team at
and Canada to play an expanding role in
VIDO-InterVac will continue to provide a
international disease control efforts. This
catalyst for research excellence that will allow
Developing creative, proactive strategies
enhanced capability is not only strategically
important for the Agriculture and Public Health
sectors but is playing an increasing role in
THE ONE WORLD ONE HEALTH
other areas important to Canada such as
movement fosters closer
international aid, global trade, tourism,
linkages between the animal,
human and environmental
economic prosperity and foreign affairs.
The future is often uncertain, especially in
health research communities
the world of infectious diseases. In the past
we have seen the emergence of numerous
Dr. Robert Clarke
Chair of VIDO-InterVac Board of Directors
2011/2012 VIDO-InterVac
BOARDOFDIRECTORS
Dr. Robert Clarke – Ontario (Chair 2011-2012)
Dr. Luis Barreto – Ontario (Chair 2010-2011)
Dr. Bill Ballantyne – Alberta
Dr. Karen Chad – Saskatchewan
Dr. Alastair Cribb – Alberta
Mr. Chris Dekker – Saskatchewan
Dr. Rainer Engelhardt – Ontario
Dr. Douglas Freeman – Saskatchewan
Mr. David Gordon – Ontario
Mr. John LaClare – Saskatchewan
Dr. Larry Milligan – Ontario
Mr. Terry Oleksyn – Saskatchewan
Mr. Don Wilson – Alberta
novel pathogens that have required rapid
Canada to play a lead role in the prevention
research response and mitigation. This has
and control of the spread of infectious
been exacerbated by the rapidly expanding
diseases. The skill and professionalism of the
air transportation industry and globalization
team was especially evident over the last few
that have created a synergism for disease
years as they continued to conduct their
impact that is unprecedented. This new
research program at the highest level while
paradigm will require creative, proactive
designing, building and commissioning a
solutions that will be at the heart of the work
highly complicated containment facility.
of VIDO-InterVac.
This level of commitment can only be
A key strategy for combating these threats
achieved through great leadership and
has been the One World One Health
dedicated staff. On behalf of the Board we
movement that fosters closer linkages
would like to thank Dr. Andy Potter and the
between the animal, human and environ -
entire VIDO-InterVac team for their tireless
mental health research communities. VIDO-
efforts and enthusiasm.
N
InterVac has for many years operated in this
way and is therefore well positioned to provide
leadership and capacity to conduct research
across a wide spectrum of hosts that will
VIDO - InterVac
I
2011-2012
I
Annual Report
I
page 4
VIDO - InterVac
I
2011-2012
I
Annual Report
I
page 5
L
Message from
the Director and CEO
ooking into the future is never an easy
In addition, alumni of VIDO-InterVac, including
task, yet the goal of most infectious
former students, post doctoral fellows and
disease researchers involves exactly
scientists continue to assist the organization in
that; the mitigation of future threats through
its efforts in both the research and global
research and development. While it is not
regulatory arenas.
possible to predict with certainty what pathogens
While VIDO-InterVac’s infrastructure is world
World class resources and expertise poised
will emerge or re-emerge in the future, one can
learn from the past and put in place proactive
InterVac gives researchers
approaches for disease control. For example,
access to one of the
we know that approximately 80% of new threats
world’s most advanced
share two properties, namely that they are
CL3 large animal facilities
usually zoonotic in nature and also require
DEVOTED TO
VACCINE RESEARCH
containment level III (CL3) facilities for their
study. Our roots in the animal health field serve
us well for the study of zoonotic pathogens,
from the development and use of relevant animal
models to our wealth of knowledge on large
animal immunology. The recent completion of the
class, that is only a set of tools that can be used
International Vaccine Centre, or InterVac, also
to prepare for future challenges. The mitigation
gives VIDO-InterVac researchers, and those
of future threats ultimately relies on the
around the globe, access to Canada’s most
individuals that make up the organization, from
advanced CL3 large animal facility devoted to
the leadership and stewardship of the Board of
vaccine research.
Directors to our researchers and staff. We have
Dr. Andrew Potter
As our former Director, Dr. Lorne Babiuk, used
continued to add to our pool of scientific expertise
Director and CEO
to say, “pathogens do not carry passports”, a
over the past year and the InterVac facility has
statement that is as true today as in the past.
also provided new opportunities for the growth
Research organizations such as VIDO-InterVac
and development of all individuals at VIDO-
must therefore maintain a presence globally in
InterVac. This group of people not only will help
order to meet the needs of their stakeholders.
mitigate the threats of future disease, but they
We have actively pursued new institutional
are VIDO-InterVac’s future as well.
N
relationships worldwide over the past year, with
new partnerships developed in China, Kenya,
South Africa and Kazakhstan to name but a few.
VIDO - InterVac
I
2011-2012
I
Annual Report
I
page 6
VIDO - InterVac
I
2011-2012
I
Annual Report
I
page 7
T
he last year has been a long anticipated
These projects aim
to develop novel vaccines
for livestock of importance to
Sub-Saharan Africa and
WILL HELP LOCAL FARMERS
CLIMB OUT OF POVERTY
one from a number of viewpoints. The
construction of InterVac was completed
and we were able to move equipment into the
by improving the
health of their animals.
laboratory and animal care space. New
equipment was purchased, and is now ready for
use as soon as InterVac is certified. Thanks to a
Identify and prioritize infectious
very dedicated group of individuals, this entire
Dr. Francois Meurens, Research Scientist, was
process went very smoothly, from the initial
recruited in April 2012 from INRA in France. Dr.
ordering to the purchasing and receiving, and
Meurens will complement our efforts to develop
finally the installation. We are grateful to all
vaccines for emerging disease and strengthen
individuals that were involved in this process.
our team of infectious disease immunologists.
Simultaneously the necessary training of
individuals began; from individual Standard
Operating Procedures to working with animals
in a BSL3 facility, to medical first responder
training. Proper training is an important aspect
to ensure that we work in a safe workplace and
I would like to thank again all individuals that
Dr. Volker Gerdts
Associate Director (Research)
were involved in these activities. A core group of
technicians were hired to set up the laboratories
and, thanks to the effort of all of these individuals
Research Highlights
As summarized below, we have made great
progress in many of our research projects and
have started several new ones, including two
international projects in food security funded by
the International Development Research Centre.
Together with partners in Kenya, South Africa
and Canada these projects aim to develop novel
vaccines for livestock in Sub-Saharan Africa and
and others; I am pleased to say that we are ready
to start the work as soon as the facility is certified.
organized our research programs and have added
RESPIRATORY
SYNCYTIAL VIRUS
a Core and Contract Research Program, managed
is the most common
by Dr. Hugh Townsend. This program manages
cause of respiratory illness
our contracts with external clients and is also
in young children, causing
responsible for core research activities of VIDO-
hundreds of thousands of
InterVac. A strategic planning process is currently
hospitalizations and
underway to identify and prioritize a list of
deaths every year.
In preparing for future challenges, we have re-
infectious disease targets for this group.
VIDO - InterVac
I
2011-2012
I
Annual Report
I
page 8
will help local farmers climb out of poverty by
improving the health of their animals.
VIDO’s research over the last three decades
has focused on both human and animal health,
and thus it is no surprise that we are close to
entering clinical trials with two new vaccine
candidates, one for human and one for veterinary
application. The first is a vaccine against
infections with Respiratory Syncytial Virus
(RSV), the most common cause of respiratory
illness in young children, causing hundreds of
thousands of hospitalizations and deaths every
Image Courtesy of International Livestock Research Institute
year. Vaccines for RSV are not available, but are
urgently needed. Led by Dr. Sylvia van den Hurk,
our researchers developed a novel vaccine that
is highly effective in both cotton rat and mouse
animal trials. Vaccinated animals were protected
against RSV infection. The vaccine was safe and
induced the right type of immunity in the
respiratory tract, a crucial requirement for
protecting young children. Funding came from
the Krembil Foundation and the Pan-Provincial
Vaccine Enterprise Inc. (PREVENT). A license
agreement was signed with PREVENT and we
anticipate the vaccine could enter clinical trials
in human volunteers within the next 16 months.
Similarly, our project to develop a vaccine for
Chronic Wasting Disease (CWD) in elk has
made great progress. Chronic wasting disease
is the most important disease of cervids in North
America and responsible for substantial economic
losses to the industry, and many elk producers
have left the industry due to the disease. This
neurological disease is similar to CreutzfeldtJakob’s Disease (CJD), bovine spongiform
encephalopathies (BSE) and even some forms
of Alzheimer’s disease and Huntington’s
disease. All of these diseases are characterized
by the misfolding of normal proteins into disease
specific forms. Misfolding of the protein leads
VIDO - InterVac
I
2011-2012
I
Annual Report
I
page 9
to malfunction, plaque formation and eventually
severe neuropathology. In collaboration with
The Porcine Reproductive
PREVENT, our researchers have developed a
and Respiratory Syndrome
vaccine for CWD. Led by Drs. Napper, Griebel
Virus is the most
and Potter, this vaccine is currently being tested
economically important
in elk and vaccines are being developed for other
disease of pigs
members of this important group of diseases.
VIDO-INTERVAC IS
DEVELOPING MORE EFFECTIVE
VACCINES.
Other research projects include diseases of
both humans and animals for which vaccines or
treatments currently are not available. Many of
these diseases are chronic in nature and are
Our project to
develop a vaccine for
CHRONIC WASTING DISEASE
in elk has made great progress.
Our researchers have
developed a vaccine currently
being tested in elk
often associated with suppression or modulation
of the immune system, a factor that complicates
humans and animals. The recent pandemic and
the development of effective treatments.
several new outbreaks of both avian and swine
Furthermore, many of these pathogens have
influenza have demonstrated the need for better
found ways to evade the immune system, or
vaccines, ideally universal vaccines that protect
due to their high genetic variability rapidly
against all circulating influenza viruses.
emerge as different and often more disease
Furthermore, an ideal vaccine would be protective
causing new strains and types.
after a single-immunization. Live attenuated
For example, infections with influenza virus
vaccines are known to induce very potent
are responsible for devastating diseases in both
immune responses after a single immunization.
Led by Dr. Yan Zhou our researchers have
developed a safe attenuated live vaccine that
protects pigs against common influenza strains.
Another important RNA virus, the Hepatitis C
virus, is a causative agent for severe liver disease
in humans, which can lead to liver steatosis and
death. Hepatitis is economically one of the most
important diseases in humans and vaccines are
still not available due to the lack of animal models
and a poorly understood pathogenesis, in
particular the interactions between the virus and
the host, and the induction of liver steatosis. Dr.
Qiang Liu and his group, members of the
Canadian Hepatitis Network, are studying the
pathways that lead to liver steatosis in order to
develop novel intervention strategies. Dr. Sylvia
van den Hurk and her group are assessing the
potential of novel dendritic-cell based vaccines
and Dr. Joyce Wilson and her team are studying
VIDO - InterVac
I
2011-2012
I
Annual Report
I
page 10
novel treatments for bacterial infections. Dr.
JoAnne Dillon and her team are investigating
the spread and mechanisms of antimicrobial
resistance amongst important pathogens such
as Neisseria gonorrhoeae and Chlamydia spp.
By combining basic research on cell division,
the group is currently identifying novel targets
for vaccines. For example, the groups identified
and characterized the gene organization of both
the division cell wall (dcw) cluster as well as
the min cluster which includes the min genesminC, minD and minE, responsible for midcell
site selection. Other pathogens of interest
include Staphylococcus aureus and Escherichia
coli (E. coli) . As World Health Organization (WHO)
coordinator for Latin America, Dr. Dillon’s group
is leading efforts on characterizing the molecular
the role of microRNAs in immunopathogenesis
Research Centre we started a new project with
and are seeking to develop ways to interfere
the International Livestock Research Institute in
Other examples of chronic infections are
with viral replication.
Kenya (ILRI) to develop vaccines against this
infections with Mycobacteria spp. These
Another highly diverse RNA virus is the Porcine
disease. Complementary, Dr. Jose Perez-Casal
pathogens cause devastating human and animal
Reproductive and Respiratory Syndrome
and his group are testing vaccines for
diseases, including human and bovine
Virus (PRRSV), responsible for the economically
Mycoplasma bovis in cattle and bison, both
tuberculosis. For example, Johne’s disease
most important disease of pigs. Current vaccines
significant problems for the North American
in cattle, an important disease caused by
are moderately effective and new strains continue
industry. In collaboration with researchers from
infection with Mycobacterium paratuberculosis
to emerge around the globe resulting in billions
the University of Alberta and the National Centre
(M. paratuberculosis) , is responsible for serious
of dollars lost annually. Led by Drs. Alexander
for Foreign Animal Diseases another project
losses to the dairy and beef industries. Research
Zakhartchouk, Meurens and Gerdts our
funded by IDRC is focused on five other viral
at VIDO is focused on using reverse vaccinology
researchers are developing novel vaccine
diseases of livestock in Sub-Saharan Africa,
to develop improved vaccines for mycobacterial
technologies that are safe and more effective
including African Swine Fever and Peste des
diseases. Drs. Scott Napper, Philip Griebel and
than existing vaccines. These are based on
Petits Ruminants.
Andrew Potter are studying host-pathogen
combinations of novel vaccine and adjuvant
epidemiology of Gonococci around the world.
Sexually transmitted diseases are on the rise
interactions in the intestine to develop novel
in Canada, especially in northern communities,
intervention strategies. To characterize the
Infections with Mycoplasma spp. are
and are becoming a major impediment to the
mechanisms by which M. paratuberculosis
responsible for significant losses to the livestock
Canadian health care system. Neisseria
evades the immune system, Drs. Napper and
industry around the world. However, especially
gonorrhoeae has achieved “superbug” status,
Griebel have developed a novel kinome
in Sub-Saharan Africa, infections with
meaning that antibiotic treatments are becoming
technology to detect post translational
Mycoplasma mycoides continue to cause
ineffective. This highlights the need for a better
phosphorylation by cell kinases , important cell
devastating losses to the local cattle industry.
understanding of the mechanisms of
molecules involved in most cell functions,
Funded by the International Development
antimicrobial resistance and the development of
including innate immune regulation. Kinome
technologies.
VIDO - InterVac
I
2011-2012
I
Annual Report
I
page 11
arrays have been developed and are now being
immunogenicity of two experimental vaccines, a
used to characterize the immune response to
riboflavin auxotroph and recombinant VapA
various pathogens.
(virulence associated protein) vaccine in neonatal
Adjuvants and novel delivery strategies are
foals.
important aspects of our vaccine development
The vectored vaccines team led by Dr.
research. Dr. Mutwiri is leading an adjuvant
Suresh Tikoo has developed a number of
research program, focused on potent
technologies based on bovine, porcine and
immunstimulators such as polyphosphazenes,
turkey adenoviruses. These vectors are highly
which are synthetic polymers used for drug and
effective in inducing balanced immune
vaccine formulation. These molecules are further
responses in both animals and humans and
optimized by our chemistry group, led by Dr.
offer a number of advantages such as safety,
Attah Poku, who has modified this class of
delivery and improved immunogenicity. Several
molecules to enhance their potential as vaccine
adenovirus-based vectors are currently being
adjuvants. Dr. Heather Wilson is investigating
generated, including a vector for African Swine
means of overcoming oral tolerance in early life,
Fever and influenza to name two. Dr. Tikoo’s
in order to vaccinate the very young. The group
group is also further characterizing the
was awarded several grants to develop vaccine
pathogenesis of bovine adenovirus.
platforms for young animals including a vaccine
Contamination of meat and meat products is
for Lawsonia intracellularis in pigs. The potential
an important concern to human health and
of a novel adjuvant platform is being assessed
vaccination represents an effective approach to
against PRRSV in pigs and human diseases such
reduce colonization in animals and subsequent
as whooping cough and RSV. Dr. Arshud Dar has
contamination of food products. Under the
used similar adjuvants to improve an
direction of Drs. Wolfgang Koester, Andrew Potter
Contamination of meat and
experimental vaccine against inclusion body
and Brenda Allen the food safety group at VIDO
meat products is an important
hepatitis in chickens, a significant disease for
is developing vaccines against Salmonella
concern to human health
the poultry industry. This group is currently
enteritidis, E. coli and C. jejuni. Vaccine candidates
developing adjuvants for in ovo-immunization of
are being evaluated in clinical studies. Dr. Aaron
poultry, the most common route of vaccine
White is studying the pathogenesis of Salmonella
administration in poultry.
and its survival in the environment, including
VIDO-INTERVAC IS
DEVELOPING FOOD SAFETY
VACCINES
against Escherichia coli,
Campylobacter jejuni and
Salmonella.
The goal of the equine vaccines project led
biofilms. Interestingly, the group has identified
by Dr. Townsend is to maintain an industry wide
various genes that facilitate survival under very
reputation for excellence in efficacy, licensing
challenging conditions and is currently assessing
and marketing (post-licensing) studies of new
means to assess the importance of these
and registered equine vaccines and to develop
antigens for future vaccines.
new vaccines for horses. This includes the study
In summary, I would like to congratulate all
of novel immune modulators as adjuvants for
members of VIDO-InterVac on the progress we
existing vaccines as well as responding to
have made in the past year. This clearly is a team
industry needs for marketing and licensing
effort and we are thankful to our staff for their
studies. The group developed a challenge model
enthusiasm and motivation to make a real impact
for Rhodococcus equi in foals and assessed the
on the health of both humans and animals.
VIDO - InterVac
I
2011-2012
I
Annual Report
I
N
page 12
Nuturing innovation in
and recognizing the needs of these
professionals will give VIDO-InterVac a
competitive advantage and help facilitate the
retention of our talented research groups.
T
It is imperative we understand that a
he world is changing. People are
challenges. For example, in the global
directional shift in our research programs will
changing. The economy is changing.
economy the competition for human capital
impact our employees and trainees, while
Globalization and advances in
is fierce. Continued success dictates that we
recognizing that change is required to ensure
technology have opened the door to many
must adapt and be resilient. We are living in
our scientific programs remain relevant. This
new opportunities, but with those
a world powered by futuristic technology and
new generation of employees have spent and
opportunities come human resource
the desire for instant information to expand
will continue to spend a large proportion of
our knowledge.
their life communicating through technology
One of the major factors that will help ensure
and expect immediate responses to their
the continued success of VIDO-InterVac will
requests. One way to ensure this group of
be our ability to recruit and manage a diverse
employees remains satisfied and engaged is
group of international talent - people that will
to promote and foster the latest tools for
bring innovative ideas, fresh perspectives and
communication, flexible work schedules,
intuitive views to our organization. We are
appropriate compensation, equal opportunities
challenged with providing a working
and consistent labour management. The
environment that supports the collaboration
senior leadership team has made
and creativity required to ensure these
implementing these a priority.
culturally diverse, highly qualified, highly
By capitalizing on the cultural diversity of
motivated professionals remain engaged while
our employees and remaining focused on the
meeting their personal and family needs.
infectious disease challenges of the future,
These personnel have roots around the globe,
VIDO-InterVac will continue to attract scientists
Ms. Joyce Sander
enabling us to greatly expand our collaborative
from the global marketplace and remain at
Associate Director (Human Resources)
research projects. Capitalizing on this diversity
the forefront of human and animal health.
N
Continued success
dictates that
WE MUST ADAPT
and be resilient
and capitalize
on the
CULTURAL
DIVERSITY OF OUR
EMPLOYEES
VIDO - InterVac
I
2011-2012
I
Annual Report
I
page 13
S
eptember 16th, 2011, marked a
momentous occasion for VIDO. After
The attendance of
the Prime Minister
the original vision of Dr. Lorne Babiuk
RAISED THE PROFILE
OF THE GRAND OPENING
SIGNIFICANTLY
and 10 years of planning, design, and
construction, the grand opening of the
International Vaccine Centre was held to
and generated much media
attention for the facility.
Cutting edge containment
exceed the parameters dictated by the
regulatory agencies. For example, we are using
independent data collection devices to record
Mr. Cam Ewart
Associate Director (Operations & Maintenance)
celebrate the completion of the world’s most
actual temperatures and pressures within our
advanced level 3 containment facility for
autoclaves in order to validate the conditions
vaccine development and infectious disease
within the units. These extra measures
research. Prime Minister Stephen Harper,
demonstrate the attention to detail and careful
Saskatchewan Premier Brad Wall, and
planning of InterVac’s construction.
Saskatoon Mayor Don Atchison were among
The process of certification, the one aspect
the many senior representatives from
of the project that is outside of VIDO’s control
government, academia, and industry who
remains ongoing. The certification process
attended the event. The attendance of the
examines the completed facility; all test reports,
Prime Minister raised the profile of the event
the validation, and the SOP’s. In late April the
significantly and generated much media
‘as-built’ and the standard operating
attention for the facility.
procedures (SOP’s) for InterVac were submitted
In March 2012 we reached the important
to the two regulatory agencies responsible for
milestone of substantial completion for InterVac,
certifying the facility; the Canadian Food
signifying the turnover of the building to the
Inspection Agency (CFIA) and the Public Health
owner. This milestone was linked to the
Agency of Canada (PHAC). Both agencies have
completion of the commissioning process,
been an integral part of the project from the
something that is uncommon in the
beginning, including the review of drawings
construction industry. However, it was important
and specifications prior to the start of
for the construction activities to be completed
construction, an interim review of SOPs, and
so that we could prove that the building would
official site inspections during construction.
operate in the manner in which it was designed.
The certification teams will be conducting a
InterVac is now fully commissioned with all
significant site inspection in the near future to
infrastructure tested and validated to ensure
ensure the facility meets all applicable
that critical systems maintain operations under
standards. Once certified, InterVac will be fully
a variety of challenging conditions. We have
operational and VIDO-InterVac will begin its
also developed commissioning procedures that
next phase of operations.
VIDO - InterVac
I
2011-2012
I
N
Annual Report
I
page 14
Top: Left to Right: Dr. Andrew Potter,
Mayor Don Atchison, U of S President Peter McKinnon,
Premier BradWall and Prime Minister Stephen Harper
reviewing the architectural drawings at the grand
opening of InterVac.
Above right: The recently commissioned InterVac
building at night.
Left: Dr. Lorne Babiuk, former Director of VIDO at the
Grand Opening.
VIDO - InterVac
I
2011-2012
I
Annual Report
I
page 15
T
he past year has provided several
have fully implemented our management
memorable moments for our
group for contract research. The focus of the
organization from both a commun -
group is to use multiple techniques to ensure
ication/marketing and business development
we deliver a quality product and enhance our
partners’ experience. This plan aligns well
with our overall goal of implementing a formal
Expanded opportunities
management system for our organization that
conforms to ISO9001 standards.
Two highlights this past year were the
execution of the first contract for InterVac
and the regulatory approval of Nuplura™ in
Dr. Paul D. Hodgson
Associate Director (Business Development)
perspective. We had the pleasure of hosting
the United States. This Novartis vaccine
the Prime Minister of Canada, the Premier of
contains technology developed at VIDO,
Saskatchewan, the Mayor of Saskatoon and
providing further evidence of the application
a variety of other dignitaries at the Grand
of our research in promoting animal health.
Opening of InterVac in September 2011. In
Internationally we continue to make progress
addition, we have been able to tour a variety
in both India and China with letters of
of stakeholder groups through InterVac to
agreement being executed in both of these
ensure they experience the magnitude of this
countries with partner institutions. These
world class level 3 research and development
agreements will provide the framework for
facility prior to certification. It is important for
more significant cooperative funding
our stakeholders to understand the
opportunities and advance research of
opportunities that InterVac provides in vaccine
importance for diseases in all countries.
development for infectious disease research
As we continue to work towards the
challenges not previously available to VIDO.
certification of InterVac we are certain this
To ensure we fully utilize this capacity we
facility will provide the additional infrastructure
have made efforts to expand our research
required to assist our staff in helping to protect
partners through enhanced marketing and
the world against future infectious disease
service delivery. As part of these efforts we
challenges.
N
Nuplura ™
CONTAINS TECHNOLOGY
DEVELOPED AT VIDO,
providing further evidence
of the application of
our research in promoting
animal health.”
VIDO - InterVac
I
2011-2012
I
Annual Report
I
page 16
F
ocusing on future challenges
cash balance increased along with funds that
has always been VIDO-InterVac’s
were received for research projects that will
philo sophy. The Finance group
be conducted in future periods.
supports this philosophy by ensuring that
VIDO-InterVac receives funding from a wide
the necessary information is available to
variety of sources, including federal and
properly manage our resources.
provincial governments, livestock industry
councils and agencies, foundations and
pharmaceutical companies (see graph). VIDO-
Managing resources
InterVac is financially accountable to these
organizations and continues to meet their
various reporting requirements which ensure
that all funding is appropriately managed.
The accounts of VIDO-InterVac itself are
In the past year revenue has increased 11%,
examined annually as a part of the Province
mainly due to additional funding from the
of Saskatchewan’s audit of the University of
Province of Saskatchewan related to InterVac.
Saskatchewan. In addition, on an annual basis
At the same time we have been able to
VIDO-InterVac’s accounts are internally
decrease expenses by 4% in 2011-2012.
reviewed by a department of the University
This was due mainly to a reduction in salary
of Saskatchewan. These various reports and
expense and related material costs, because
reviews guarantee that the resources of VIDO-
of the successful completion of several post-
InterVac are used wisely to achieve the
doctoral positions. The other expenses
organizations objectives.
remained consistent with the prior year or
and interesting time for VIDO-InterVac. As
decreased slightly, (see graph).
Mr. Lorne Vanin
Associate Director (Finance)
The near future will be a very important
Additionally, Capital assets increased
always, the finance group will support the
substantially in 2011-2012, as InterVac was
management of the organization to help
readied for future operation. VIDO-InterVac’s
ensure its future success.
Sources of Revenue
N
Annual Expense Comparison (in millions)
8
7
Conditional grants 53%
6
Province of Saskatchewan 25%
5
University of Saskatchewan 13%
4
Other income 5%
3
2
Contract research 4%
Unconditional funds 0%
1
0
Salaries
2012
VIDO - InterVac
I
2011-2012
I
Annual Report
I
page 17
Materials
2011
Travel
Amortization
Other
VIDO - InterVac
I
2011-2012
I
Annual Report
I
page 18
Unaudited
INTERNALLY RESTRICTED FUNDS
INVESTMENT IN CAPITAL ASSETS
EQUITY
UNEARNED REVENUE (Schedule 1)
CURRENT LIABILITIES
Accounts payable
Accrued vacation pay
LIABILITIES
Long Term Accounts Receivable (Note 3)
Investments
Capital Assets (Note 5)
LONG TERM ASSETS
Funds held - University of Saskatchewan
Accounts receivable (Note 3)
Inventories (Note 4)
CURRENT ASSETS
ASSETS
$ 44,680,730
29,520,093
$ 13,854,852
15,665,241
15,160,637
14,186,464
974,173
427,476
546,697
13,147,801
12,569,722
578,079
105,937
472,142
$ 40,869,389
27,721,588
$ 13,229,510
14,492,078
$
$ 40,869,389
$ 44,680,730
$
175,000
10,917,044
14,492,078
15,285,267
17,694,182
245,663
11,075,644
15,665,241
$ 8,631,931
6,536,329
117,007
2011
$ 11,222,033
6,334,189
137,960
2012
Unaudited
13,854,852
15,665,241
INTERNALLY RESTRICTED FUNDS
INVESTMENT IN CAPITAL ASSETS
$ 29,520,093
$ 29,520,093
$ 27,721,588
13,229,510
14,492,078
$ 27,721,588
106,589
27,614,999
11,223,367
10,788,851
1,798,505
27,721,588
6,600,922
2,537,232
144,851
299,315
355,907
47,283
1,202,537
35,320
11,329,956
$ 1,788,135
4,568,001
1,131,035
877,941
522,460
75,079
503,549
31,000
1,831,139
7,750
(6,134)
2011
6,407,298
2,458,717
339,698
312,007
238,249
42,646
974,638
15,598
12,587,356
$ 1,459,164
7,050,623
701,365
577,287
552,740
195,307
415,014
16,200
1,613,860
9,484
(3,688)
2012
FUND BALANCES, END OF YEAR
EXCESS OF EXPENDITURE OVER INCOME
FUND BALANCES, BEGINNING OF YEAR
EXPENDITURE
Salaries and benefits
Materials and supplies
Equipment repair and service agreements
Sub-contract research
Travel and recruiting
Patents and legal fees
Amortization
Other expenditures (Note 6)
INCOME
Conditional grants
Government of Canada
Government of Saskatchewan
Other Governments
Non-Government
Commercial contract research
Royalties and Licensing Fees
Investment income
Unconditional revenue
University of Saskatchewan
Miscellaneous Income
Gain (loss) on disposal of capital assets
FOR THE YEAR ENDED APRIL 30, 2012
STATEMENT OF OPERATIONS
STATEMENT OF FINANCIAL POSITION
AS AT APRIL 30, 2012
UNIVERSITY OF SASKATCHEWAN
VACCINE & INFECTIOUS DISEASE ORGANIZATION-INTERNATIONAL VACCINE CENTRE
UNIVERSITY OF SASKATCHEWAN
VACCINE & INFECTIOUS DISEASE ORGANIZATION-INTERNATIONAL VACCINE CENTRE
Review
T
he University of Saskatchewan's Financial Reporting Department has examined the
Financial Statements as prepared by VIDO and have found that the figures presented
therein reconcile to the University's financial records. In addition, Financial Reporting
has reviewed the adjusting transactions and have concluded that the adjustments are reaOctober 2, 2012
sonable and accurate. Therefore, the University of Saskatchewan can confirm that the statements
as presented by VIDO are accurate and in accordance with the University's financial policies.
Financial statement users are cautioned that these statements have not been audited or
reviewed for purposes other than those described above.
Scott Caswell, B. Admin, CA
Financial Analyst, Financial Reporting
Financial Services Division, University of Saskatchewan
VIDO-InterVac
VIDO - InterVac
I
2011-2012
I
Advancing Canadian Agriculture
and Agrifood
Agriculture and Agri-Food Canada
Agriculture and Food Council of
Alberta
Alberta Agricultural Research
Institute
Alberta Beef Producers
Alberta Chicken Producers
Alberta Food Council
Alberta Innovates- Bio Solutions
Alberta Livestock and Meat Agency
Alberta Livestock Industry
Development Fund
Alberta Prion Research Institute
Becker-Underwood Inc.
Bill & Melinda Gates Foundation
Bioniche Life Sciences Inc.
Boehringer Ingelheim Vetmedica
Inc.
Canada Foundation for Innovation
Canadian Institutes of Health
Research
Canadian Poultry Research Council
Canadian Swine Health Board
Cangene Corporation
Cattle Industry Development
Council
CEVA Sante Animale
Annual Report
I
page 19
DeNovaMed Inc.
Genome AB
Genome BC
Government of Canada Department
of Foreign Affairs and International
Trade
Government of Canada Department
of National Defense
Government of Manitoba
Department of Agriculture, Food
and Rural Initiatives
Government of Saskatchewan
Department of Advanced Education,
Employment and Labour
Government of Saskatchewan
Department of Agriculture and Food
Government of Saskatchewan
Enterprise and Innovation
Health Sciences North
International Development
Research Centre
Jarislowsky Chair in Biotechnology
Management
Kamloops Stockmen’s Association
Krembil Foundation
Maple Leaf Foods Inc.
Meadow Ridge Enterprises
Merial Limited
National CIHR Research Training
Program
National Pork Board
National Veterinary Research and
Quarantine Service- Korea
Natural Sciences & Engineering
Research Council of Canada
Novartis Animal Health Canada Inc.
Novartis Animal Health U.S.,Inc.
Ontario Cattlemen’s Association
Ontario Ministry of Agriculture Food
and Rural Affairs
Pan-Provincial Vaccine Enterprise
Inc. (PREVENT)
Poultry Industry Council
Prevtec Microbia Inc.
PrioNet Canada
Sanofi Pasteur
Saponin, Inc.
Saskatchewan BeeKeepers’s
Association
Saskatchewan Chicken Industry
Development Fund
Saskatchewan Health Research
Foundation
Saskatchewan Horned Cattle Trust
Fund
Shastri Indo-Canadian Institute
Synbiotics Corporation
University of Alberta
University of British Columbia
University of Calgary
Valorisation-Recherche, S.E.C.
World Health Organization
VIDO-InterVac
Vaccine and Infectious Disease Organization International Vaccine Centre
Vaccine and Infectious Disease Organization – International Vaccine Centre
120 Veterinary Road , Saskatoon, SK Canada S7N 5E3
www.vido.org